AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01964131 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: D961H HPMC capsule 20 mg
Description: Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
Study NCT02373878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telecoaching plus Plate
Description: A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
Study NCT02373878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects were provided with institutional pamphlets on healthy eating and exercise habits
Study NCT01695148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-Carotene Biofortified Maize Flour
Study NCT01695148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White Maize Flour
Study NCT01908920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment
Study NCT01908920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SHAM
Study NCT01908920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CONTROL
Study NCT04268264 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional haemodialysis
Description: three times weekly 4-hour long haemodialysis sessions from the start
Study NCT03332797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545
Description: GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study NCT03332797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study NCT03332797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
Study NCT03392337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrowband UVB phototherapy
Description: Ultraviolet B phototherapy
Study NCT02744508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron
Study NCT02744508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron with dexamethasone
Study NCT04136236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endoscopist
Description: Suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI. After a washout period, nonexpert endoscopists take the second assessment with AI assistance.
Study NCT03166878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART019
Description: Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
Study NCT04824131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cabotegravir (CAB)
Description: 30 mg tablets
Study NCT04824131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Study NCT04824131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: 300 mg/200 mg fixed-dose combination tablets
Study NCT03444779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial Tuberoplasty
Description: Kyphoplasty ballon
Study NCT03444779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open technique
Description: Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
Study NCT03686384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVT-15652
Description: 1 vial twice daily
Study NCT03686384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 vial twice daily
Study NCT03461042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
Study NCT03461042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily before bedtime for 12 weeks since informed consent
Study NCT06674200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenteric Molding Suturing Group
Description: During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues.
Study NCT06674200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regular
Description: The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues.
Study NCT02919098 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bystander, a game-based bystander intervention program
Description: A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
Study NCT02919098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander, a game-based bystander intervention program
Description: A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
Study NCT02919098 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Infection City, a game-based program about meningitis
Description: A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
Study NCT04603053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: Participants will receive access to CBot-A app for 12 weeks.
Study NCT02739165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
Study NCT02739165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by intravenous drip infusion in addition to standard of care steroid therapy
Study NCT02946320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predilatation with non-compliant balloon
Description: Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
Study NCT02946320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilatation with scoring balloon (Scoroflex)
Description: Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
Study NCT02946320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilatation with cutting balloon (Flextome)
Description: Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
Study NCT02922595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation through ILMA®
Description: It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed
Study NCT02922595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation through ILTS®
Description: It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed
Study NCT00604305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof
Description: Monofocal IOL
Study NCT00604305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuity's AIOL
Description: Accommodating IOL
Study NCT04357366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
Study NCT04295473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced port laparoscopic gastrectomy
Description: The ports were reduced in the surgery of intervention arm.
Study NCT03851380 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological / Functional Assessment
Description: Psychological and functional assessment battery to characterize participants.
Study NCT03851380 — intervention group
Intervention type: OTHER
Intervention: Structural and Functional MRI
Description: Structural and functional magnetic resonance imaging session.
Study NCT03851380 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Brain Stimulation and MR Image Guidance
Description: MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
Study NCT03851380 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Electrical Stimulation (tES)
Description: Home-based Transcranial Direct Current Stimulation
Study NCT01850563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
Study NCT00664469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg/day over a 6-week course of treatment.
Study NCT00664469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Simvastatin 20, 40 and 80 mg
Description: Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study NCT00664469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Atorvastatin
Description: Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study NCT00664469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rosuvastatin
Description: Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study NCT00648843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-release Tablets 5 mg
Description: 4x5mg, single dose fed
Study NCT04007211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT13107
Description: Dose: 3mL, maximum 10mL
Study NCT04007211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalobarrier
Description: Dose: 10mL
Study NCT01795638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Study NCT00648843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 5 mg
Description: 4x5mg, single dose fed
Study NCT04297670 — intervention group
Intervention type: OTHER
Intervention: Measurement of HPV types prevalence
Description: Self collected genital samples to be tested for the presence of different HPV types.
Study NCT01795638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
Study NCT01889550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to the website www.graviditetsportalen.dk
Description: The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
Study NCT01889550 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Access to the website www.ouh.dk
Description: Access to the usual information from the hospital website
Study NCT06459960 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Heated pool (32°C); Convention rehabilitation + Hydrotherapy
Study NCT06459960 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Convention
Description: Convention rehabilitation only
Study NCT03547830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor for Conditioning before HSCT.
Study NCT03547830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gcsf
Description: GCSF for Conditioning before HSCT.
Study NCT00007787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study NCT00007787 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Study NCT00007787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-human thymocyte globulin (rabbit)
Description: Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
Study NCT00007787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT00007787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT01712451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate, fluticasone propionate
Description: LIPO-102
Study NCT01712451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01712451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: Salmeterol
Study NCT03791541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist services
Description: Additional pharmacist/pharmacy student follow-ups, counseling, and other services
Study NCT05544656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
Study NCT05544656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo administered three times a day
Study NCT02845011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual compression feedback
Description: The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
Study NCT02845011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Manual Chest Compression
Description: Cardiopulmonary resuscitation according to published international guidelines.
Study NCT00545116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
Study NCT00545116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
Study NCT01066130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive individualized psychosocial treatment
Description: Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
Study NCT01066130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal treatment arm
Description: Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
Study NCT03427801 — intervention group
Intervention type: DRUG
Intervention: Erythropoiesis-Stimulating Agent
Description: erythropoiesis-stimulating agent: Mircera or Darbepoietin
Study NCT03559127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: For the Group A. Applied Cryotherapy at 6 oC
Description: Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
Study NCT03559127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: For the Group B. Applied Cryotherapy at 2.5 oC
Description: Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
Study NCT03559127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Group (CG). Applied irrigant at room temperature
Description: Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
Study NCT04712916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
Study NCT02311517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
Study NCT02311517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01195116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 mcg/kg/hour
Study NCT01195116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1mcg/kg/hr
Study NCT04309162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue therapy
Description: Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
Study NCT02413424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2mM sucralose
Study NCT02413424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 60 ml of water
Study NCT02413424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose load
Study NCT02413424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose load
Study NCT02525276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.